glp 1 agonist delayed gastric emptying GLP-1 medications safe to continue before surgery in patients with diabetes and obesity All patients on GLP1 agonists
Description
J Biomed Sci (2017) 24(1):76
doi: 10.1111/jsr.70196 46
A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity
In the obesity trial, serious adverse events (SAEs) occurred in 4% of participants with retatrutide use overall (06% across groups) vs
doi: 10.1111/dom.14089 231 SamsonSLGarberA
